PAG
AQST icon

Private Advisor Group’s Aquestive Therapeutics AQST Stock Holding History

Private Advisor Group’s Portfolio AQST Stock Details AQST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-1,300
Closed -$6K – 1663
2020
Q2 		$6K Buy
+1,300
New +$5.99K ﹤0.01% 3137

Other funds holding AQST

BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BCL
Bracebridge Capital LLC Boston, Massachusetts $3.73B AUM 33.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Private Advisor Group's AQST Position: Q3 2020 in Review

Private Advisor Group sold out of Aquestive Therapeutics (AQST) in Q3 2020, closing a stake of 1,300 shares — an estimated $6K sold.

Private Advisor Group first reported a position in AQST in Q2 2020 and held it in 1 quarter. The position peaked at $6K in Q2 2020. 60 funds tracked by Wall St. Rank hold AQST as of Q3 2020.

  • Private Advisor Group reported no remaining Aquestive Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Private Advisor Group sold 1,300 Aquestive Therapeutics shares in Q3 2020, an estimated $6K.
  • Private Advisor Group first reported a position in Aquestive Therapeutics in Q2 2020 and held it in 1 quarter.
  • Private Advisor Group's Aquestive Therapeutics position peaked at $6K in Q2 2020.
  • 60 funds tracked by Wall St. Rank held Aquestive Therapeutics as of Q3 2020.

Based on Private Advisor Group's 13F filing for Q3 2020, filed 2 Nov 2020.